Background:Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.We sought to determine whether alirocumab,a human monoclonal antibody to proprotein convertase ...Background:Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.We sought to determine whether alirocumab,a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9(PCSK9),would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.展开更多
文摘Background:Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.We sought to determine whether alirocumab,a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9(PCSK9),would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.
